ELU-001 is under clinical development by Elucida Oncology and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ELU-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ELU-001 is under development for the treatment of relapsed and refractory acute myeloid leukemia, colorectal cancer, cholangiocarcinoma, epithelial ovarian cancer, fallopian tube cancer, endometrial cancer, gastric cancer, gastroesophageal junction cancer, hematological malignancies, non-small cell lung cancer, ovarian cancer, platinum resistant, triple negative breast cancer, metastatic brain tumor (brain metastases) and for other solid tumors. The drug candidate is a small molecule drug conjugate (SMDC) consisting of folate moeity conjugated with topoisomerase 1 inhibitor. It acts by targeting folate receptor. It is being developed based on targeted nanoparticle C’Dot drug conjugate technology. It is administered through intravenous route.
Elucida Oncology overview
Elucida Oncology is a biotechnology company that develops products based on nanoparticle delivery platform which helps to detect and treat cancer.
For a complete picture of ELU-001’s drug-specific PTSR and LoA scores, buy the report here.